2-Phenyl-4,5-dichlorpyrimidin | 26740-69-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-Phenyl-4,5-dichlorpyrimidin
• 英文别名: 4,5-dichloro-2-phenyl-pyrimidine；4,5-Dichloro-2-phenylpyrimidine
• CAS: 26740-69-2
• 化学式: C₁₀H₆Cl₂N₂
• 分子量: 225.077
• InChiKey: VASKWKROZNSZGG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] INHIBITORS OF INTERLEUKIN-1 RECEPTOR ASSOCIATED KINASE (IRAK) /FMS-LIKE RECEPTOR TYROSINE KINASE (FLT3), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF<br/>[FR] INHIBITEURS DE LA KINASE ASSOCIÉE AU RÉCEPTEUR DE L'INTERLEUKINE 1 (IRAK)/TYROSINE KINASE DU RÉCEPTEUR DE TYPE FMS (FLT3), LEURS PRODUITS PHARMACEUTIQUES ET LEURS PROCÉDÉS
  申请人：PHARMABLOCK SCIENCES NANJING INC

  公开号：WO2021159993A1

  公开（公告）日：2021-08-19

  Inhibitors of interleukin-1 receptor associated kinase (IRAK) enzyme/FMS-like receptor tyrosine kinase (FLT3) with Formula (I), a pharmaceutically acceptable salt, ester, prodrug, complex, solvate, hydrate, or isomer thereof, in any crystalline form or in amorphous form. In Formula (I), X, X 1, X 2 is selected from N and C; and U, V and W groups are independently of each other a non-hydrogen monovalent group. Pharmaceutical products comprising the IRAK inhibitors and prophylaxis and/or treatment of inflammatory diseases, autoimmune diseases, and proliferative diseases, among others, are also provided. The interleukin-1 receptor associated kinase (IRAK) mentioned above can be IRAK4.

  具有公式（I）的白细胞介素-1受体相关激酶（IRAK）酶/类FMS受体酪氨酸激酶（FLT3）的抑制剂，其为药用可接受的盐、酯、前药、复合物、溶剂化物、水合物或其异构体，在任何晶体形式或非晶形式中。在公式（I）中，X、X1、X2从N和C中选择；U、V和W基团是非氢单价基团，彼此独立。还提供了包括IRAK抑制剂的药物产品以及预防和/或治疗炎症性疾病、自身免疫性疾病和增殖性疾病等。上述提到的白细胞介素-1受体相关激酶（IRAK）可以是IRAK4。
• Substituted Pyridazinyl- and Pyrimidinyl-Quinolin-4-Ylamine Analogues
  申请人：Caldwell Timothy M.

  公开号：US20080175794A1

  公开（公告）日：2008-07-24

  Substituted pyridazinyl- and pyrimidinyl-quinolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

  本发明提供了替代吡啶并嘧啶基喹啉-4-胺类似物。此类化合物是配体，可以用于调节体内或体外特定受体的活性，并在治疗与人类、家畜伴侣动物和家畜动物中的病理性受体激活相关的疾病方面特别有用。本发明还提供了制备这些药物组合物和使用它们治疗这些疾病的方法，以及使用此类配体进行受体定位研究的方法。
• Microencapsulated herbicides
  申请人：Monsanto Technology LLC

  公开号：US11129381B2

  公开（公告）日：2021-09-28

  Herbicidal microcapsules containing a combination of herbicides are described. In particular, the herbicidal microcapsules include a core material comprising an acetamide herbicide and a second herbicide and a shell wall encapsulating the core material. Also described are processes for preparing the microcapsules, various herbicidal compositions containing the microcapsules, and methods of preparing and using the herbicidal compositions.

  描述了含有除草剂组合的除草微胶囊。特别是，除草微胶囊包括由乙酰胺除草剂和第二种除草剂组成的芯材和封装芯材的壳壁。还描述了制备微胶囊的工艺、含有微胶囊的各种除草组合物以及制备和使用除草组合物的方法。
• HERBIZID-KOMBINATION MIT ACYLIERTEN AMINOPHENYLSULFONYLHARNSTOFFEN
  申请人：Aventis CropScience GmbH

  公开号：EP1231839A2

  公开（公告）日：2002-08-21
• PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP1318997A1

  公开（公告）日：2003-06-18